Heron Therapeutics Inc vs Roivant Sciences Ltd. Common Shares — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $68.01M), while Roivant Sciences Ltd. Common Shares trades at $34.21 (market cap $24.72B). The key difference: Roivant Sciences Ltd. Common Shares is far larger — about 363.5× Heron Therapeutics Inc's market cap, and Roivant Sciences Ltd. Common Shares is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Roivant Sciences Ltd. Common Shares for 0 Days on average.
| HRTX | ROIV | |
|---|---|---|
Market Cap | $68.01M | $24.72B |
Volume | 1,891,941 | 6,279,442 |
Sector | Health | Health |
52-Week High | $1.49 | $41.81 |
52-Week Low | $0.27 | $16.04 |
Typical Hold Time | 35 Days | 0 Days |
Enterprise Value | $174.75M | $20.99B |
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →